Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic Biomarker.

IL-8 advanced CRC anti-angiogenic drugs chemotherapy prognosis tumor–stroma interactions

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
19 Oct 2022
Historique:
received: 15 09 2022
revised: 09 10 2022
accepted: 16 10 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 28 10 2022
Statut: epublish

Résumé

Among soluble actors that have emerged as druggable factors, the chemokine interleukin-8 (IL-8) has emerged as a possible determinant of response to immunotherapy and targeted treatment in several cancer types; however, its prognostic/predictive role in colorectal cancer (CRC) remains to be established. We: (i) conducted a systematic review of published literature on IL-8 expression in CRC; (ii) searched public transcriptomics databases; (iii) investigated IL-8 expression, by tumor and infiltrating cells, in a series of CRC samples; and (iv) carried out a meta-analysis of published literature correlating IL-8 expression and CRC prognosis. IL-8 possesses an important role as a mediator of the bidirectional crosstalk between tumor/stromal cells. Transcriptomic analysis indicated that specific IL-8 transcripts were significantly overexpressed in CRC compared to normal colon mucosa. Moreover, in our series we observed a statistically significant correlation between PTEN-loss and IL-8 expression by infiltrating mononuclear and tumor cells. In total, 12 papers met our meta-analysis inclusion criteria, demonstrating that high IL-8 levels significantly correlated with shorter overall survival and progression-free survival. Sensitivity analysis demonstrated a highly significant correlation with outcome for circulating, but not for tissue-detected, IL-8. IL-8 is overexpressed in CRC tissues and differentially produced by tumor or stromal components depending on CRC genetic background. Moreover, circulating IL-8 represents a strong prognostic factor in CRC, suggesting its use in the refining of prognostic CRC assessment and potentially the tailoring of therapeutic strategies in individual CRC patients.

Identifiants

pubmed: 36289899
pii: biomedicines10102631
doi: 10.3390/biomedicines10102631
pmc: PMC9599846
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Bando Interno Ricerca Corrente IRE 2021
ID : n.a.
Organisme : Italian Association for Cancer Research
ID : AIRC IG 20583
Organisme : Ministry of Education, Universities and Research
ID : B39J21037270006
Organisme : Ministero della Salute
ID : FIMPCUP_J38D19000690001
Organisme : Italian Association for Cancer Research
ID : n.a.

Références

Cells. 2022 Jun 09;11(12):
pubmed: 35741003
Br J Cancer. 2020 Aug;123(4):610-618
pubmed: 32488137
BMC Cancer. 2014 Jul 28;14:542
pubmed: 25069793
Theranostics. 2017 Apr 7;7(6):1543-1588
pubmed: 28529637
Int J Mol Sci. 2020 Dec 24;22(1):
pubmed: 33374459
J Leukoc Biol. 2002 Nov;72(5):847-55
pubmed: 12429706
J Oncol. 2019 May 5;2019:5373580
pubmed: 31191652
Cell Commun Signal. 2020 Mar 30;18(1):52
pubmed: 32228650
Acta Clin Belg. 2021 Apr;76(2):113-118
pubmed: 31610752
Science. 2015 May 8;348(6235):648-60
pubmed: 25954001
Br J Cancer. 2019 Feb;120(3):340-345
pubmed: 30636774
Cancer Manag Res. 2018 Nov 14;10:5659-5666
pubmed: 30532588
Cancer Chemother Pharmacol. 2018 Jun;81(6):1111-1119
pubmed: 29693201
Cancer Drug Resist. 2019 Dec 19;2(4):968-979
pubmed: 35582268
Front Immunol. 2022 Mar 17;13:795972
pubmed: 35371084
Br J Cancer. 2011 Feb 1;104(3):480-7
pubmed: 21285972
Int J Cancer. 2015 Feb 1;136(3):584-92
pubmed: 24916890
PLoS One. 2015 Apr 09;10(4):e0123484
pubmed: 25856316
Nat Med. 2020 May;26(5):693-698
pubmed: 32405063
Cytokine. 2020 Nov;135:155205
pubmed: 32721849
Clin Cancer Res. 2019 May 1;25(9):2887-2899
pubmed: 30705034
BMC Cancer. 2014 May 10;14:330
pubmed: 24885636
Int J Colorectal Dis. 2021 Jan;36(1):131-139
pubmed: 32920703
Cancer Med. 2013 Apr;2(2):234-42
pubmed: 23634291
Br J Cancer. 2013 Nov 26;109(11):2765-73
pubmed: 24149180
J Immunol. 2003 Mar 15;170(6):3369-76
pubmed: 12626597
Neoplasia. 2009 Aug;11(8):720-31
pubmed: 19649202
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Cancer Lett. 2015 May 28;361(1):22-32
pubmed: 25687885
Biochem Biophys Res Commun. 2011 Nov 18;415(2):245-51
pubmed: 22037460
Int J Mol Sci. 2016 Apr 28;17(5):
pubmed: 27136535
J Immunother Cancer. 2019 Sep 5;7(1):240
pubmed: 31488216
Int J Oncol. 2020 Jun;56(6):1551-1564
pubmed: 32236629
Clin Cancer Res. 2020 Sep 1;26(17):4661-4669
pubmed: 32532788
Commun Biol. 2020 Oct 1;3(1):546
pubmed: 33004975
J Clin Oncol. 2010 Jan 20;28(3):453-9
pubmed: 20008624
Lancet Oncol. 2015 Aug;16(8):937-48
pubmed: 26184520
Int J Cancer. 2014 Aug 1;135(3):731-41
pubmed: 24374727
Int J Oncol. 2022 Jan;60(1):
pubmed: 34913066
Can J Gastroenterol Hepatol. 2018 Jun 11;2018:7436205
pubmed: 29992127
Int J Cancer. 2011 May 1;128(9):2038-49
pubmed: 20648559
Nat Med. 2020 May;26(5):688-692
pubmed: 32405062
Nucleic Acids Res. 2022 Jan 7;50(D1):D988-D995
pubmed: 34791404
Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):2769-2784
pubmed: 29751081
Gastroenterol Rep (Oxf). 2020 Jun 23;8(3):179-191
pubmed: 32665850
Oncotarget. 2017 Mar 7;8(10):16887-16898
pubmed: 28129643
Int J Mol Sci. 2019 Nov 20;20(23):
pubmed: 31756952

Auteurs

Chiara Bazzichetto (C)

Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Michele Milella (M)

Section of Oncology, Department of Medicine, University of Verona-School of Medicine and Verona University Hospital Trust, 37134 Verona, Italy.

Ilaria Zampiva (I)

Section of Oncology, Department of Medicine, University of Verona-School of Medicine and Verona University Hospital Trust, 37134 Verona, Italy.

Francesca Simionato (F)

Department of Oncology, San Bortolo General Hospital, 36100 Vicenza, Italy.

Carla Azzurra Amoreo (CA)

Pathology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Simonetta Buglioni (S)

Pathology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Chiara Pacelli (C)

Department of Biochemical Sciences "A. Rossi Fanelli", Sapienza University of Rome, 00185 Rome, Italy.

Loredana Le Pera (L)

Servizio Grandi Strumentazioni e Core Facilities, Istituto Superiore di Sanità (ISS), 00161 Rome, Italy.

Teresa Colombo (T)

Institute of Molecular Biology and Pathology-National Research Council (IBPM-CNR), 00185 Rome, Italy.

Emilio Bria (E)

Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.

Massimo Zeuli (M)

Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Donatella Del Bufalo (D)

Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Isabella Sperduti (I)

Biostatistics Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Fabiana Conciatori (F)

Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.

Classifications MeSH